Anaplastic Thyroid Cancer
3 competing products in clinical development for Anaplastic Thyroid Cancer.
Pipeline by Phase
Phase 1/21
Phase 22
All Products (3)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Lenvatinib + Nivolumab | Ono Pharmaceutical | Phase 2 | Active | 39 |
| efatutazone + paclitaxel | Daiichi Sankyo | Phase 2 | Completed | 35 |
| CS-7017 + Paclitaxel | Daiichi Sankyo | Phase 1/2 | Terminated | 24 |